Skip to main content
. 2021 Jan 15;7:609322. doi: 10.3389/fmolb.2020.609322

Figure 3.

Figure 3

Subgroup analysis of PFS. TACE, transarterial chemoembolization; Sor, sorafenib; ICIs, immune checkpoint inhibitors; PFS, Progression-free survival; OS, overall survival.